GCP has a few case studies that are useful, e.g. Recursion Pharma: https://cloud.google.com/customers/recursion/
710 karma · joined September 26, 2014
1. Terms of service seem over-bearing (see @whydoineedthis)
2. Show me a demo before making me provide personal info (email) and consent.
3. Yellow button on yellow background, ugh
4. "Made with happiness and abundant goodness." Cool, prove it. Show me who's behind this.
Latent Sciences is an AI-first predictive medicines company dedicated to solving neurodegenerative diseases [1]. We're soon emerging from stealth mode, with exciting big-pharma projects and impactful clinical trial deployments. We're looking for a SW Architect to lead the development of our data/ML pipelines, with potential for growing into a Director of Engineering role. Main req's:
- Deep experience implementing platforms and data solutions in at least one of the following industries: genomics, biopharma, med tech/device, payer, provider. Ideally you've run the gamut from infrastructure/devops to consumer-facing desktop/mobile applications.
- Desire to build something new, thinking strategically about business, product, and technical challenges. As one of the first few hires you'll be influential in defining the company culture and path to success.
Sound like you? Drop us a note: careers@latentsci.com
[1] www.latentsci.com
Yes, and your example of AuralAnalytics points out the two classes of angles:
1. Different modalities -- brain imaging, voice, eye movements, memory exams, etc*
2. Different diseases -- there are many similarities in underlying processes of neurodegen diseases, but there are many complexities that makes each one a unique, difficult to understand pathophysiology
*Etc is the exciting area, w/ startups still in stealth
On the new life sciences support,
1. How do you know which companies? Do we need to explicitly sign-up/transfer to a life sciences program?
2. Are the life sciences rewards in addition to or replacing the standard Brex rewards [1]?
Also a feature request while you're here: Easy payment a la Chase QuickPay.
Latent Sciences is an AI-first predictive medicines company dedicated to solving neurodegenerative diseases [1]. We're soon emerging from stealth mode, with exciting big-pharma projects and impactful clinical trial deployments. We're looking for a SW Architect to lead the development of our ML pipelines, with potential for growing into a Director of Engineering role. Main req's:
- Deep experience implementing platforms and data solutions in at least one of the following industries: genomics, biopharma, med tech/device, payer, provider. Ideally you've run the gamut from infrastructure/devops to consumer-facing desktop/mobile applications.
- Desire to build something new, thinking strategically about business, product, and technical challenges. As one of the first few hires you'll be influential in defining the company culture and path to success.
Sound like you? Drop us a note: careers@latentsci.com
[1] www.latentsci.com
[1] https://www.nasa.gov/lunarcatalyst
[2] https://www.nasa.gov/feature/nasa-extends-agreements-to-adva...
- The most outrageously patient human being alive.
- "1+1 = 2". So you're saying 3 is not a number?
- This is the most impressive display of dealing with a hostile interviewer I have seen in my life
- Jordan Peterson: Hi
Cathy Newman: So you are saying "Heil Hitler"?
https://github.com/numenta/NAB/tree/master/data#real-data
Ahmad & Lavin, Neurocomputing 2016, https://www.sciencedirect.com/science/article/pii/S092523121...
[1] https://bitbucket.org/gtborg/gtsam
[2] https://github.com/borglab/gtsam/tree/develop/examples#kalma...
[3] e.g., https://github.com/gtrll/piper and https://github.com/gtrll/gpmp2
2. Premise 1 is agreeable. P2 doesn't hold past the initial VC demo, let alone MVP stage. P3: probably approximately correct. P4: I would agree.
3. Skimming the comments here and seeing mixed/confused feedback, I assume those taking this more seriously are keeping silent.
> I always lean towards solving the problem today vs. problems 5 years down the road
Are you alluding to the problem of setting up w/ Carta, suggesting to bite that bullet now vs five years from now?
If so, the former calls for paying a few grand for the same capabilities of a free captable service, but the latter could a pain b/c the captable/stakeholders would be much more complex in several years.
- David Ha w/ Google Brain: https://twitter.com/hardmaru
- Adam Gibson started Skymind in Silicon Valley and moved to Tokyo a few years back: https://twitter.com/agibsonccc
Do you have an automated way of doing this? I keep the Downloads/ finder tab open at all times so I periodically clean up.
A salient quote from the article:
> However, what makes OpenAI’s decision puzzling is that it seems to presume that OpenAI is somehow special—that their technology is somehow different than what everyone else in the entire NLP community is doing—otherwise, what is achieved by withholding it? However, from reading the paper, it appears that this work is straight down the middle of the mainstream NLP research. To be clear, it is good work and could likely be published, but it is precisely the sort of science-as-usual step forward that you would expect to see in a month or two, from any of tens of equally strong NLP labs.